KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Other financing activities (2019 - 2025)

Vir Biotechnology's Other financing activities history spans 5 years, with the latest figure at -$2000.0 for Q4 2025.

  • For Q4 2025, Other financing activities fell 115.38% year-over-year to -$2000.0; the TTM value through Dec 2025 reached -$28000.0, up 83.03%, while the annual FY2025 figure was -$361000.0, 118.79% down from the prior year.
  • Other financing activities for Q4 2025 was -$2000.0 at Vir Biotechnology, down from $1000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $100000.0 in Q1 2023 and bottomed at -$387000.0 in Q4 2023.
  • The 4-year median for Other financing activities is -$21000.0 (2024), against an average of -$89125.0.
  • The largest annual shift saw Other financing activities soared 103.36% in 2024 before it crashed 115.38% in 2025.
  • A 4-year view of Other financing activities shows it stood at -$260000.0 in 2022, then tumbled by 48.85% to -$387000.0 in 2023, then skyrocketed by 103.36% to $13000.0 in 2024, then plummeted by 115.38% to -$2000.0 in 2025.
  • Per Business Quant, the three most recent readings for VIR's Other financing activities are -$2000.0 (Q4 2025), $1000.0 (Q3 2025), and $13000.0 (Q4 2024).